Liminatus Pharma Inc Class A Ordinary Shares LIMN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.15
- Day Range
- $0.13–0.14
- 52-Week Range
- $0.10–4.33
- Bid/Ask
- $0.13 / $0.13
- Shares Outstanding
- 67.16M
- Market Cap
- $9.40M
- Volume/Avg
- 13M / 40M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- http://liminatuspharma.com
Valuation
|
Metric
|
LIMN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 26.07 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
LIMN
Financial Strength
|
Metric
|
LIMN
|
|---|---|
Quick Ratio | 0.99 |
Current Ratio | 1.12 |
Interest Coverage | −164.79 |
Quick Ratio
LIMN
Profitability
|
Metric
|
LIMN
|
|---|---|
Return on Assets (Normalized) | −548.94% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LIMN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^rlBp<^ | LOCK|>S&c | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%!$%?< | LOCK|$k!> | $83B | |||
| argenx SE ADR
ARGX
| LOCK|xPhzc!% | LOCK|wd< | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|My%X^LWB | LOCK|PL^# | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|D@^?js | LOCK|?K | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$ljzdv | LOCK|!bZ< | $31B | |||
| Moderna Inc
MRNA
| LOCK|G!>$D! | LOCK|WB | $25B | |||
| Incyte Corp
INCY
| LOCK|Ch?@wP# | LOCK|@rK | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Ht>&>> | LOCK|$&> | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|nMk^mb? | LOCK|lT@ | $16B |
United States